In response to the full set of peptides, the number of IFNγ-producing cells was not significantly modified by immunosuppressive treatment (SpA patients receiving anti-TNF drugs (n = 21), P = 0.39; RA patients receiving anti-TNF drugs (n = 19), P = 0.19; RA patients receiving MTX (n = 22), P = 0.58) (Figure 3b), nor was the number of EBV-specific IFNγ-producing T cells modified when considering each set of peptides (latent-cycle peptides or lytic-cycle peptides) (data not shown). Here, IFNG is linked to rheumatoid arthritis.